Topotecan-d6
(Synonyms: (4S)-10-[[二(三氘甲基)氨基]甲基]-4-乙基-4,9-二羟基-1H-吡喃并[3',4':6,7]吲哚嗪并[1,2-B]喹啉-3,14(4H,12H)-二酮) 目录号 : GC45888An internal standard for the quantification of topotecan
Cas No.:1044904-10-0
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Topotecan-d6 is intended for use as an internal standard for the quantification of topotecan by GC- or LC-MS. Topotecan is an inhibitor of DNA topoisomerase I and a derivative of the DNA topoisomerase I inhibitor camptothecin .1,2,3 Topotecan inhibits DNA topoisomerase I in human MCF-7 breast and DU145 prostate cancer cells with IC50 values of 13 and 2 nM, respectively, in a cell-based luciferase reporter assay.4 Topotecan induces cytotoxicity and DNA damage in HT-29 human colon adenocarcinoma cells (IC50s = 33 and 280 nM, respectively).1 Formulations containing topotecan have been used in the treatment of small-cell lung cancer.
|1. Rothenberg, M.L. Topoisomerase I inhibitors: Review and update. Ann. Oncol. 8(9), 837-855 (1997).|2. Dancey, J., and Eisenhauer, E.A. Current perspectives on camptothecins in cancer treatment. Br. J. Cancer 74(3), 327-338 (1996).|3. Schellens, J.H., Creemers, G.J., Beijnen, J.H., et al. Bioavailability and pharmacokinetics of oral topotecan: A new topoisomerase I inhibitor. Br. J. Cancer 73(10), 1268-1271 (1996).|4. Caceres, G., Zankina, R., Zhu, X., et al. Determination of chemotherapeutic activity in vivo by luminescent imaging of luciferase-transfected human tumors. Anticancer Drugs 14(7), 569-574 (2003).
Cas No. | 1044904-10-0 | SDF | |
别名 | (4S)-10-[[二(三氘甲基)氨基]甲基]-4-乙基-4,9-二羟基-1H-吡喃并[3',4':6,7]吲哚嗪并[1,2-B]喹啉-3,14(4H,12H)-二酮 | ||
Canonical SMILES | O=C([C@]1(O)CC)OCC2=C1C=C(C(N=C(C=CC(O)=C3CN(C([2H])([2H])[2H])C([2H])([2H])[2H])C3=C4)=C4C5)N5C2=O | ||
分子式 | C23H17D6N3O5 | 分子量 | 427.5 |
溶解度 | aqueous acid: soluble,Methanol: soluble | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.3392 mL | 11.6959 mL | 23.3918 mL |
5 mM | 0.4678 mL | 2.3392 mL | 4.6784 mL |
10 mM | 0.2339 mL | 1.1696 mL | 2.3392 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。